Skip to main content

ABCD Nationwide Semaglutide Audit Publications

Papers, abstracts, presentations, posters and webcasts emanating from the audit

Webcast

EASD 2021: Crabtree, T. S. J., K. Adamson, H. Reid, D. Barnes, S. Sivappriyan, A. Bickerton, I. W. Gallen, and R. E. J. Ryder. "The use of semaglutide alongside other diabetes medications: real-world results from the Association of British Clinical Diabetologists (ABCD) audit programme." In DIABETOLOGIA, vol. 64, no. SUPPL 1, pp. 236-237. ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES: SPRINGER, 2021. https://youtu.be/f6_bMVyFWjw

 

Published papers

Thomas SJ Crabtree, Karen Adamason, Alex Bickerton, Alison Evans, Suzanne Phillips, Alison Gallagher, Niels Larsen, Dennis Barnes, Ketan Dhatariya, Benjamin CT Field, Iskaner Idris, Robert EJ Ryder, on behalf of all ABCD semaglutide audit contributors. The factors predicting glucose and weightresponse to injectable semaglutide (Ozempic):real-world data from the Association of BritishClinical Diabetologists’ audit programme. The British Journal of Diabetes, Volume 23 Issue 2 / December 2023
DOI: https://doi.org/10.15277/bjd.2023.418

 

Crabtree, T. S. J., K. Adamson, H. Reid, D. Barnes, S. Sivappriyan, A. Bickerton, I. W. Gallen, B. C. T. Field, I. Idris, and R. E. J. Ryder. "Injectable semaglutide and reductions in HbA1c and weight in the real‐world in people switched from alternative glucagon‐like peptide 1 receptor agonists." Diabetes, Obesity and Metabolism (2022). https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14701

All contributors are listed 
 

Slides from presentations

EASD 2022 Semaglutide 1st and 2nd Oral Slides

 

Abstracts

Thomas S.J. Crabtree, Devesh K. Sennik, Alex Bickerton, Dennis Barnes, Siva Sivappriyan, Karen  Adamson, Suzanne M. Phillips, Alison Evans, Niels Larsen, Avinash Panesar, Melissa L. Cull, Ian W. Gallen, Iskandar R. Idris, Robert E. Ryder. 756-P: The Effect of Semaglutide on Alanine Aminotransferase (ALT) Levels: Results from the Association of British Clinical Diabetologists (ABCD) Audit. Diabetes 2022;71(Supplement_1):756-P DOI: https://doi.org/10.2337/db22-756-P

 

T. S. J. Crabtree, A. Gallagher, I. Gallen, A. Melvin, J. Elliott, A. Bickerton, K. Dhatariya, G. Rayman, R. E. J. Ryder. The effect of sodium-glucose link transporter 2 inhibitors (SGLT2i) on microalbuminuria: Cross-class analysis from the ABCD audit programme. Diabetic Medicine,Volume 39, Issue S1: A41 (P230) 

Oral Abstract: https://onlinelibrary.wiley.com/doi/10.1111/dme.14809

Poster Abstract: https://onlinelibrary.wiley.com/doi/10.1111/dme.14810,

 

T. S. J. Crabtree, K. Adamson, H. Reid, D. Barnes, S. Sivappriyan, A. Bickerton, I. W. Gallen, A. Gallagher, I. Idris, R. E. J. Ryder. Predictors of HbA1c and weight response to semaglutide: Results from the Association of British Clinical Diabetologists (ABCD) audit programme. Diabetic Medicine,Volume 39, Issue S1:A56 (P231) 

Oral Abstract: https://onlinelibrary.wiley.com/doi/10.1111/dme.14809

Poster Abstract: https://onlinelibrary.wiley.com/doi/10.1111/dme.14810

 

Posters 

ADA June 2022
EASD 2022
DUK Professional Conference March 2022 
ADA June 2021 
ABCD Virtual Meeting December 2020
 

 

The ABCD nationwide semaglutide audit is an independent audit supported by an unrestricted grant from Novo Nordisk